⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
27,395 patients with stable atherosclerotic vascular disease randomized to rivaroxaban 2.5mg BID + aspirin 100mg, rivaroxaban 5mg BID, or aspirin 100mg alone. Trial stopped for superiority after 23 months. Primary outcome (CV death + stroke + MI): 4.1% vs 5.4% (HR 0.76, p<0.001) for rivaroxaban+aspirin vs aspirin. More major bleeding with rivaroxaban+aspirin (3.1% vs 1.9%). All-cause mortality lower (3.4% vs 4.1%, HR 0.82, p=0.01). Funded by Bayer (COMPASS).
Coeff. authors = avg(0.40, 0.70) = 0.55
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.55, 0.95) = 0.55← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.55
Final score = 49.0/52.8 × 0.55 × 100 = 51/100
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follo…
Rothwell PM — 2010 · Lancet (London, England)
Contrasted resultsCardiovascular Disease, Drug Therapy, and Mortality in Covid-19.
Mehra MR — 2020 · The New England Journal of Medicine
Contrasted resultsEfficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Tardif JC — 2019 · The New England Journal of Medicine
Contrasted resultsBlood pressure lowering for prevention of cardiovascular disease and death: a systemati…
Ettehad D — 2016 · Lancet (London, England)
Contrasted resultsDietary cholesterol and cardiovascular disease: a systematic review and meta-analysis.
Berger S — 2015 · The American journal of clinical nutrition